


CLAIMS

1. A compound of formula I:











wherein:

X_1 and X_2 each independently represent N or CR_a

R_a independently represents H, NH_2 , halo, C_{1-5} alkyl, C_{1-5} alkoxy, C_{2-5} alkenyl and C_{2-5} alkynyl (which latter four groups are unsubstituted or substituted by one or more halo substituents);

A is selected from the group consisting of:




where:

the dotted line represents the point of attachment to the rest of the molecule;

R₁ is selected from halo, C₁₋₅ alkyl, C₁₋₅ alkoxy, C₂₋₅ alkenyl, C₂₋₅ alkynyl, piperazine, methylpiperazine, ethylpiperazine, which latter seven groups are unsubstituted or substituted by one or more halo substituents, and where the piperazine, methylpiperazine and ethylpiperazine may be connected to the rest of moiety A *via* a carbon or nitrogen atom in the piperazine ring;

each R₂, and R₅ is independently selected from halo, C₁₋₅ alkyl, C₁₋₅ alkoxy, C₂₋₅ alkenyl, C₂₋₅ alkynyl, which latter four groups are unsubstituted or substituted by one or more halo substituents;

each R_3 and R_4 is independently selected from halo, C_{1-5} alkyl, C_{1-5} alkoxy, C_{2-5} alkenyl, C_{2-5} alkynyl (which latter four groups are unsubstituted or substituted by one or more halo substituents), NH_2 , OH , and a group of the formula:




where R_{10} and R_{14} are each independently selected from H, F and Cl,

R_{11} , R_{12} and R_{13} are each independently selected from H, F, Cl and NH_2 ,

X_{10} , X_{11} , X_{12} , X_{13} and X_{14} are each independently selected from CH and N,

X_3 represents N, CH or CR_3 , where R_3 is as defined above, X_4 represents N, CH or CR_4 , where R_4 is as defined above, X_5 represents N, CH or CR_5 , where R_5 is as defined above, provided that only one or two of X_3 to X_5 is N;

each X_6 and X_7 independently represents N, CH, CR_{6a} , where each R_{6a} is independently selected from C_{1-5} alkyl, C_{1-5} alkoxy, C_{2-5} alkenyl, C_{2-5} alkynyl (which four groups are unsubstituted or substituted by one or more halo substituents), NH_2 , OH or a group of the formula:



, where R₁₀ to R₁₄ and X₁₀ to X₁₄ are as defined above;


each X₈ and X₉ independently represents N, CH or CR_{6b}, where each R_{6b} is independently selected from C₁₋₅ alkyl, C₁₋₅ alkoxy, C₂₋₅ alkenyl, C₂₋₅ alkynyl, which four groups are unsubstituted or substituted by one or more halo substituents;

Y₁ represents NR_N, O or S;

Y₂ represents NR_N, NR_Y, O or S;

R_N represents H, C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, which latter three groups are unsubstituted or substituted by one or more halo substituents;

R_Y represents NH₂, OH or a group of the formula:



, where R₁₀ to R₁₄ and X₁₀ to X₁₄ are as defined above;

L is a linking group of the formula:

$-M-(CR_LR_M)_a-C(O)-NR_7-$;

$-M-(CR_LR_M)_a-NR_7-C(O)-$; or

$-M-C(O)-(CR_NR_O)-C(O)-M-$

where M represents a covalent bond, O or NH;


R_L and R_M each independently represent H, methyl, ethyl, fluoro or chloro, or R_L and R_M together form a C_3 or C_4 cycloalkyl ring, carbonyl or thiocarbonyl group;


a represents 0 or 1;

R_7 and R_7' represent H or an optionally substituted alkyl group;

R_N and R_O each independently represent H, methyl, ethyl, fluoro or chloro, or R_N and R_O together form a C_3 or C_4 cycloalkyl ring;

Z represents a heterocycle selected from the group consisting of:






where:

the dotted line represents the point of attachment to the rest of the molecule, and Z is attached to the rest of the molecule *via* a covalent bond, or *via* a -O- or -NH- group;

each of R₈ to R₁₀ are independently selected from H, hydroxy, C₁ to C₅ alkyl, C₁ to C₅ alkoxy (which latter two groups are unsubstituted or substituted by one or more halo groups), OC(O)R₁₁, C(O)OR₁₂, C₂ to C₅ alkynyl (which is unsubstituted or substituted by one or more halo groups) or NR₁₃R₁₄, and O-(C₁₋₄ alkenenyl)-O-C₁₋₄ alkyl,

and one of R₈ to R₁₀ may be a group of the formula:



where X represents O or NR_x;


R_x represents H or C₁₋₄ alkyl,

R₁₁ and R₁₂ each independently represent, at each occurrence, optionally substituted alkyl;


R₁₃ and R₁₄ each independently represent, at each occurrence, H or optionally substituted alkyl;

R₁₅ represents H or C₁₋₂ alkyl; or

a pharmaceutically acceptable salt, solvate or derivative thereof,



provided that when X_1 and X_2 are both CH, L is , and A is



, then Z is not an optionally substituted heteroaryl selected from optionally substituted tetrazolyl or optionally substituted imidazopyridinyl.

2. A compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein R_a independently represents H, NH_2 , F, Cl, or C_{1-3} alkyl, which C_{1-3} alkyl group is unsubstituted or substituted by one, two or three fluoro or chloro substituents,

optionally wherein R_a is H or F.

3. A compound according to Claim 1 or 2, wherein X_1 is selected from N and CH, and X_2 is selected from CH and CF.

4. A compound according to any one of Claims 1 to 3, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

each R_1 to R_5 independently represents halo, C_{1-3} alkyl, C_{1-3} alkoxy, C_{2-3} alkenyl and C_{2-3} alkynyl (which four groups are unsubstituted or substituted by one or more halo substituents), optionally wherein each R_1 to R_5 independently represents fluoro, chloro, methyl or ethyl, which methyl and ethyl groups may be unsubstituted or substituted by one, two or three fluoro or chloro groups.

5. A compound according to Claim 1 or 2, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

Y_1 and Y_2 independently represent O, NC_{1-3} alkyl or NH; and/or

R_6 independently represents C_{1-3} alkyl, C_{1-3} alkoxy, C_{2-3} alkenyl and C_{2-3} alkynyl (which four groups are unsubstituted or substituted by one or more halo substituents),

optionally wherein Y_1 and Y_2 independently represent O, NMe or NH, and/or

R_6 independently represents fluoro, chloro, methyl or ethyl, which methyl and ethyl groups may be unsubstituted or substituted by one, two or three fluoro or chloro groups.

6. A compound according to Claim 4, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein each of R_1 to R_5 and R_6 independently represents methyl, trifluoromethyl, fluoro or chloro.


7. A compound according to any one of the preceding Claims, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

(a) each R_8 to R_{10} independently represents H, hydroxy, Me, C_{1-2} alkoxy (which is unsubstituted or substituted by one or more halo groups), $OC(O)R_{11}$, $C(O)OR_{12}$, C_2 to C_3 alkynyl (which is substituted by one or more halo groups), $O-(C_{1-2} \text{ alkylene})-O-C_{1-2} \text{ alkyl}$, or $NR_{13}R_{14}$,

R_{11} and R_{12} each independently represent methyl or ethyl,

R_{13} and R_{14} each independently represent H, methyl or ethyl; or

(b) one of R_8 to R_{10} represents a group of the formula




where X represents O, or NH, or $N-C_{1-2} \text{ alkyl}$,

R_{15} represents methyl,

and the remaining two of R_8 to R_{10} are as defined in part (a).

8. A compound according to any one of the preceding Claims, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein Z represents a heterocycle selected from:




9. A compound according to any one of the preceding Claims, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

- (a) when any of R_8 to R_{10} is a C_1 to C_5 alkyl group, it is an unsubstituted methyl group; and/or
- (b) when any of R_8 to R_{10} is a C_2 to C_5 alkynyl group, it is a C_2 to C_5 alkynyl group which is substituted by one or more halo groups.

10. A compound according to any one of the preceding Claims, wherein:


R_9 and R_{10} , when present, are H, and/or




R_8 is selected from H and

, where X is O or NH.

11. A compound according to any one of any one of the preceding Claims, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein A is selected from the group consisting of:



12. A compound according to Claim 11, wherein A is selected from the group consisting of:



and where when present:

R₁ is selected from Cl and CH,

R₂ is CF₃,

X₃ and X₅ are CH,

X₄ is N,

X₆ is N,

X₈ and X₉ are CH,

Y₂ is selected from N-CH₃ and O.


13. A compound according to any one of the preceding Claims, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

M represents O or NH; and/or


R_L and R_M each independently represent H, methyl or chloro, or R_L and R_M together represent thiocarbonyl or cyclopropyl; and/or


a represents 1.

14. A compound according to any one of the preceding Claims, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein L is selected from:




15. A compound according to any one of Claims 1 to 13, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein L is selected from:

















optionally wherein L is selected from




16. A compound according to Claim 1 which is selected from







or a pharmaceutically acceptable or a salt, solvate or derivative thereof.

17. A compound according to Claim 1, which is selected from:







or a pharmaceutically acceptable salt, solvate or derivative thereof.

18. Use of a compound of formula I as defined in any one of Claims 1 to 17, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the manufacture of a medicament to treat one or more of cancer (e.g. prostate cancer, colon cancer, rectal cancer, colorectal cancer, acute myeloid leukaemia or chronic myelomonocytic leukaemia) and angiogenesis.

19. A method of treating one or more of cancer (e.g. prostate cancer, colon cancer, rectal cancer, colorectal cancer, acute myeloid leukaemia or chronic myelomonocytic leukaemia) and angiogenesis, which method comprises administering a therapeutically effective amount of a compound of formula as defined in any one of Claims 1 to 17 or a pharmaceutically acceptable salt, solvate or derivative thereof.

20. A compound of formula I as defined in any one of Claims 1 to 17 or a pharmaceutically acceptable salt, solvate or derivative thereof, for use in treating one or more of cancer (e.g. prostate cancer, colon cancer, rectal cancer, colorectal cancer, acute myeloid leukaemia or chronic myelomonocytic leukaemia) and angiogenesis.


21. A pharmaceutical composition comprising a compound of formula I as defined in any one of Claims 1 to 17 or a pharmaceutically acceptable salt, solvate or derivative thereof.


22. A compound according to Claim 1, or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

X_1 and X_2 each independently represent N or CR_a

R_a independently represents H, NH_2 , halo, C_{1-5} alkyl, C_{1-5} alkoxy, C_{2-5} alkenyl and C_{2-5} alkynyl (which latter four groups are unsubstituted or substituted by one or more halo substituents);

A is selected from the group consisting of:





where:

the dotted line represents the point of attachment to the rest of the molecule;

each R_1 to R_5 is independently selected from halo, C_{1-5} alkyl, C_{1-5} alkoxy, C_{2-5} alkenyl, C_{2-5} alkynyl, which latter four groups are unsubstituted or substituted by one or more halo substituents;


X_3 represents N, CH or CR_3 , where R_3 is as defined above, X_4 represents N, CH or CR_4 , where R_4 is as defined above, X_5 represents N, CH or CR_5 , where R_5 is as defined above, provided that only one or two of X_3 to X_5 is N;


each X_6 to X_9 independently represents N, CH or CR_6 , where each R_6 is independently selected from C_{1-5} alkyl, C_{1-5} alkoxy, C_{2-5} alkenyl, C_{2-5} alkynyl, which four groups are unsubstituted or substituted by one or more halo substituents;

Y_1 and Y_2 each independently represent NR_N , O or S;

R_N represents H, C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, which latter three groups are unsubstituted or substituted by one or more halo substituents;

L is a linking group of the formula:






where M represents a covalent bond, O or NH;

R_L and R_M each independently represent H, methyl, ethyl, fluoro or chloro, or R_L and R_M together form a C_3 or C_4 cycloalkyl ring, carbonyl or thiocarbonyl group;

a represents 0 or 1;

R_7 and R_7' represent H or an optionally substituted alkyl group;


Z represents a heterocycle selected from the group consisting of:



where:

the dotted line represents the point of attachment to the rest of the molecule, and Z is attached to the rest of the molecule *via* a covalent bond, or *via* a -O- or -NH- group;


each of R_8 to R_{10} are independently selected from H, Me, C_1 to C_5 alkoxy which is unsubstituted or substituted by one or more halo groups, $OC(O)R_{11}$, $C(O)OR_{12}$, C_2 to C_5 alkynyl substituted by one or more halo groups or $NR_{13}R_{14}$, and one of R_8 to R_{10} may be a group of the formula



where X represents O or NH


R_{11} and R_{12} each independently represent, at each occurrence, optionally substituted alkyl;

R_{13} and R_{14} each independently represent, at each occurrence, H or optionally substituted alkyl;



provided that when X_1 and X_2 are both CH, L is

, and A is



, then Z is not an optionally substituted heteroaryl selected from optionally substituted tetrazolyl or optionally substituted imidazopyridinyl.